Journal article Open Access

REVIEW ON BIOMARKERS: TOOL FOR DIAGNOSIS OF A DISEASE AND DRUG DEVELOPMENT

Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.3264828</identifier>
  <creators>
    <creator>
      <creatorName>Sandip S. Kshirsagar, Vaishali R. Shinde, Manjusha Nevase, Sayali Dudhal</creatorName>
      <affiliation>Kasturi Shikshan Sanstha's College of Pharmacy, Shikrapur, Pune-412207, Maharashtra, India.</affiliation>
    </creator>
  </creators>
  <titles>
    <title>REVIEW ON BIOMARKERS: TOOL FOR DIAGNOSIS OF A DISEASE AND DRUG DEVELOPMENT</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2019</publicationYear>
  <subjects>
    <subject>Biomarker, Diagnostic Biomarkers, Surrogate Markers.</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2019-06-30</date>
  </dates>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/3264828</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3264827</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/iajpr</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. In this review we discuss the intrinsic properties of biological sample based efficacy measurements and how these relate to their implementation in oncology drug development by way of points to consider and examples. In short use of biomarker data will help us make the best possible use of precious human samples and maximize the chances of success of the most promising therapeutic approaches.&lt;/p&gt;</description>
  </descriptions>
</resource>
49
35
views
downloads
All versions This version
Views 4949
Downloads 3535
Data volume 29.4 MB29.4 MB
Unique views 4949
Unique downloads 3535

Share

Cite as